MRNS - マリナス・ファ―マシュ―ティカルズ （Marinus Pharmaceuticals Inc.） マリナス・ファ―マシュ―ティカルズMRNSのチャート
MRNSの企業情報
| symbol | MRNS |
|---|---|
| 会社名 | Marinus Pharmaceuticals Inc （マリナス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Marinus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate ganaxolone is a modulator being developed in various dose forms including intravenous oral capsule and oral liquid intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications including adjunctive or add-on therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome and PCDH19 pediatric epilepsy. マリナス・ファ―マシュ―ティカルズは精神神経疾患の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。成人てんかん、PCDH119遺伝子変異てんかん、脆弱X染色体症候群の治療用合成ニュ―ロステロイドganaxolone（経口剤)の治験を行う。また、急性発作患者に対するganaxoloneの点滴剤の開発を行う。 Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. |
| 本社所在地 | 170 N. Radnor Chester Rd. Suite 250 Radnor PA 19087 USA |
| 代表者氏名 | Christopher M. Cashman Christopher M. Cashman |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 484-801-4670 |
| 設立年月日 | 37834 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 16人 |
| url | www.marinuspharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mrns |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.66500 |
| 終値（lastsale） | 7.37 |
| 時価総額（marketcap） | 298669345.81 |
| 時価総額 | 時価総額（百万ドル） 231.80310 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 185.43410 |
| 当期純利益 | 当期純利益（百万ドル） -24.41100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Marinus Pharmaceuticals Inc revenues was not reported. Net loss increased 55% to $15.5M. Higher net loss reflects Other Research and Development increase of 72% to $10.3M (expense) Stock-based Compensation in SGA increase of 68% to $1.6M (expense) Stock-based Compensation in R&D increase from $370K to $816K (expense). |
MRNSのテクニカル分析
MRNSのニュース
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022 2022/04/20 11:30:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results 2022/04/14 11:00:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates 2022/04/01 19:16:50 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it. The month of March saw several approvals coming through, while outright rejection and postponements were few and far between. Three new molecular entities, or NMEs, were approved during the month. NMEs are drugs that contain active moieties that haven''t been previously approved by the FDA. It''s, therefore, an indicator of innovation in drug research. Marinus Pharmaceuticals, Inc.''s (NASDAQ: MRNS ) Ztalmy, indicated to treat seizures associated with a rare genetic condition known as CDKL-5 deficiency disorder (CDD), was among the NMEs that scored win the FDA in March. H.C. Wainwright analyst Douglas Tsao expects peak U.S. sales potential of $92 million for Ztalmy, given CDD is a relatively small market. Other NMEs approved during the month included Bristol-Myers Squibb Company''s (NYSE: BMY ) melanoma combo therapy Opdualag and Novartis AG''s (NYSE: NVS ) Pluvicto for treating a certain type of advanced, castration-resistant prostate cancer.
Marinus Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/03/22 18:10:45 Seeking Alpha
Marinus Pharmaceuticals higher as Truist and JMP raises price target after FDA approved ZTALMY 2022/03/22 16:36:30 Seeking Alpha
Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals <> to $50 from $35 and maintains a Buy rating on the shares
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results 2022/04/14 11:00:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates 2022/04/01 19:16:50 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it. The month of March saw several approvals coming through, while outright rejection and postponements were few and far between. Three new molecular entities, or NMEs, were approved during the month. NMEs are drugs that contain active moieties that haven''t been previously approved by the FDA. It''s, therefore, an indicator of innovation in drug research. Marinus Pharmaceuticals, Inc.''s (NASDAQ: MRNS ) Ztalmy, indicated to treat seizures associated with a rare genetic condition known as CDKL-5 deficiency disorder (CDD), was among the NMEs that scored win the FDA in March. H.C. Wainwright analyst Douglas Tsao expects peak U.S. sales potential of $92 million for Ztalmy, given CDD is a relatively small market. Other NMEs approved during the month included Bristol-Myers Squibb Company''s (NYSE: BMY ) melanoma combo therapy Opdualag and Novartis AG''s (NYSE: NVS ) Pluvicto for treating a certain type of advanced, castration-resistant prostate cancer.
Marinus Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/03/22 18:10:45 Seeking Alpha
Marinus Pharmaceuticals higher as Truist and JMP raises price target after FDA approved ZTALMY 2022/03/22 16:36:30 Seeking Alpha
Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals <> to $50 from $35 and maintains a Buy rating on the shares
Analyzing Marinus Pharmaceuticals Inc''s Short Interest 2022/03/22 13:25:38 Benzinga
Marinus Pharmaceuticals Inc''s (NASDAQ: MRNS ) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short , which is 3.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of … Full story available on Benzinga.com
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting 2021/12/03 15:01:00 Business Wire
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
California State Teachers Retirement System Boosts Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) 2021/11/25 10:20:41 Transcript Daily
California State Teachers Retirement System increased its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 15.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,899 shares of the biopharmaceutical company’s stock after purchasing an additional 6,962 shares during the period. […]
FY2021 EPS Estimates for Marinus Pharmaceuticals, Inc. Increased by SVB Leerink (NASDAQ:MRNS) 2021/11/13 06:12:42 Dakota Financial News
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts at SVB Leerink upped their FY2021 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a research note issued to investors on Tuesday, November 9th. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($2.75) per share for the year, up from their []
SVB Leerink Comments on Marinus Pharmaceuticals, Inc.s FY2024 Earnings (NASDAQ:MRNS) 2021/11/12 09:24:42 Transcript Daily
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Research analysts at SVB Leerink increased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a note issued to investors on Tuesday, November 9th. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will earn $1.25 per share for the year, up from their previous []